It has been a green year for marijuana stocks as some have rallied over 100% as sales growth for legal marijuana continues to increase. The marijuana industry has changed rapidly as the perception of marijuana continues to be viewed in a more positive light than ever before, which is budding the pockets of investors.
An increased number of marijuana stocks possess market caps over $1 billion which continues to make the marijuana market more attractive to investors. Here are the top three pure-play marijuana stocks in terms of market cap.
Canopy Growth Corp (TWMJF) $3.02 billion
Canopy Growth is the king of marijuana stocks and has the highest individual market share in the thriving Canadian medical marijuana market. The company has just reported second quarter earnings showing a massive 107% increase in revenue from the year prior. The deal Canopy achieved with Fortune 500 Constellation Brands (STZ), which invested $245 million for a 9.9% stake into the company for collaboration of marijuana infused beverages was a game changer for the industry.
Canopy continues to expand its growing operations as Canada’s national legalization of recreation marijuana can add billions to its revenue. The company isn’t just expanding domestically either but abroad as well adding to its list of countries where it exports its medical marijuana such as Spain, Jamaica, Denmark, Germany.
GW Pharmaceuticals (GWPH) $2.84 billion
GW Pharmaceuticals once upon a time was the ruler of marijuana kingdom and now comes in as second. The company concentrates on the discovery of cannabinoids to utilize them to influence a positive biologic change.
The company’s star candidate, Epidiolex, is an oral cannabidiol-based drug that is presently in pivotal-stage trial. In two different phase-three studies, Epidiolex had proven a substantial drop in seizure occurrence for both Dravet syndrome and Lennox-Gastaut syndrome, two rare forms of childhood epilepsy. If the drug is approved by the FDA, it would be the first in class cannabinoid-based drug to go on the market. Sales are forecasted to surpass $500 million annually.
Aurora Cannabis (ACBFF) $1.47 billion
Aurora Cannabis is another Canadian medical marijuana cultivator that been part of the green rush this year showing a 103% gain, but its market cap is just about half of the two top leaders in the industry.
What has caught investors’ attention is the Aurora Sky project. The project is an 800,000 square-foot mostly automated facility that when complete shall have the capability of producing 100,000 kilograms of dried marijuana per year. With Aurora Sky being mostly mechanized the company is anticipated to have the lowest growing costs and highest margins in the entire industry. Aurora will be ready to meet the high demands that recreational legalization will be and ready to reap the profits as well.
It has been a green year for marijuana stocks as some have rallied over 100% as sales growth for legal marijuana continues to increase. The marijuana industry has changed rapidly as the perception of marijuana continues viewed more positively than ever before, which is budding the pockets of investors.
An increased number of marijuana stocks possess market caps over $1 billion which continues to make the marijuana market more attractive to investors. Here are the top three pure-play marijuana stocks in terms of market cap.
Canopy Growth Corp (TWMJF) $3.02 billion
Canopy Growth is the king of marijuana stocks and has the highest individual market share in the thriving Canadian medical marijuana market. The company has just reported second quarter earnings showing a massive 107% increase in revenue from the year prior. The deal Canopy achieved with Fortune 500 Constellation Brands (STZ), which invested $245 million for a 9.9% stake into the company for collaboration of marijuana infused beverages was a game changer for the industry.
Canopy continues to expand its growing operations as Canada’s national legalization of recreation marijuana can add billions to its revenue. The company isn’t just expanding domestically either but abroad as well adding to its list of countries where it exports its medical marijuana such as Spain, Jamaica, Denmark, Germany.
GW Pharmaceuticals (GWPH) $2.84 billion
GW Pharmaceuticals once upon a time was the ruler of marijuana kingdom and now comes in as second. The company concentrates on the discovery of cannabinoids to utilize them to influence a positive biologic change.
The company’s star candidate, Epidiolex, is an oral cannabidiol-based drug that is presently in pivotal-stage trial. In two different phase-three studies, Epidiolex had proven a substantial drop in seizure occurrence for both Dravet syndrome and Lennox-Gastaut syndrome, two rare forms of childhood epilepsy. If the drug is approved by the FDA, it would be the first in class cannabinoid-based drug to go on the market. Sales are forecasted to surpass $500 million annually.
Aurora Cannabis (ACBFF) $1.47 billion
Aurora Cannabis is another Canadian medical marijuana cultivator that been part of the green rush this year showing a 103% gain, but its market cap is just about half of the two top leaders in the industry.
What has caught investors’ attention is the Aurora Sky project. The project is an 800,000 square-foot mostly automated facility that when complete shall have the capability of producing 100,000 kilograms of dried marijuana per year. With Aurora Sky being mostly mechanized the company is anticipated to have the lowest growing costs and highest margins in the entire industry. Aurora will be ready to meet the high demands that recreational legalization will be and ready to reap the profits as well.
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
